Latest News and Press Releases

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other...

Phase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation stage, with announcement of recommended Phase 2 dose and Phase 1 data expected in Q4 2022 Lanraplenib...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious...

Data in the second half of 2023 could potentially lead to accelerated approvalIf approved, entospletinib would be the first treatment for newly diagnosed patients with the NPM1 mutation who are fit...

Initial data demonstrate long plasma half-life and dose-dependent target inhibition Trial is continuing to enroll patients on three-day on, four-day off schedule SAN MATEO, Calif. and CAMBRIDGE,...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...

Company today announces progression of two discovery programs within its pipeline Highlights from the quarter include presentation of preclinical data on the company’s CDK9 inhibitor KB-0742 at...

Kronos to receive broad access to Tempus’ real-world data and proprietary tools and materials to expand preclinical hypotheses testing capabilities and inform more streamlined clinical trial design ...

SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...